. . "5-HMT: 50% to albumin and alpha1-acid glycoprotein "@en . . "Fesoterodine"@en . . . . . "Take with or without food."@en . . . . . "For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence)."@en . . . "IV, 5-HMT: 169 L "@en . "Renal: 70% of fesoterodine was recovered in urine as 5-HMT; 35% carboxy metabolite; 18% carboxy-N-desisopropylmetabolite, and 1% N-desisopropyl metabolite Fecal: 7% Hepatic: fesoterodine elimination via CYP2D6 and CYP3A4"@en . . "Humans and other mammals"@en . . "approved"@en . . . . . "# Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21545485 # Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC: The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19835561"@en . . . . . . "286930-03-8"@en . "Tmax (5-HMT): 5 hours post-adminitration of fesoterodine. AUC (0,\u221E)= 49.5 ng\u00B7h/ ml Bioavailability, 5-HMT = 52% "@en . . . . "Claus Meese, \"CHIRAL INTERMEDIATE, PROCESS FOR PRODUCING THE SAME AND ITS USE IN THE MANUFACTURE OF TOLTERODINE, FESOTERODINE, OR THE ACTIVE METABOLITE THEREOF.\" U.S. Patent US20090192224, issued July 30, 2009."@en . . . . . . . "Fesoterodine"@en . . "Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome."@en . . "Fesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder."@en . . . . "5-HMT, healthy subjects: 14.4 L/h 5-HMT is also secreted into the nephron. "@en . . . . . . "Rat, Oral, LD50: ~ 681 mg/kg Mouse, Oral, LD50: ~ 316 mg/kg Rat, Intravenous, NOAEL: 10 mg/kg Mouse, Intravenous, NOAEL: 10 mg/kg"@en . "7-8 hours for the active metabolite 5-hydroxymethyl tolterodine "@en . "FESO"@en . . . . . " "@en . " "@en . .